Literature DB >> 25546727

Global transcriptome and sequenome analysis of formalin-fixed salivary epithelial-myoepithelial carcinoma specimens.

Isabel Fonseca1, Achim Bell, Khalida Wani, Diana Bell.   

Abstract

Diverse microarray and sequencing technologies have been widely used to characterize molecular changes in malignant epithelial cells in salivary neoplasms. Such gene expression studies to identify markers and targets in tumor cells are, however, compromised by the cellular heterogeneity of these tumors and by the difficulties to accrue matching controls representing normal salivary glands. Seventeen samples of primary salivary epithelial-myoepithelial carcinoma along with tissue from six normal major salivary glands were microdissected from paraffin-embedded tissue. Pools of RNA from highly enriched preparations of these cell types were subjected to expression profiling using a whole-transcriptome shotgun sequencing experiment. In parallel, extracted genomic DNA was used for the 50 gene hotspot panel sequenome. KRAS mutations in three patients (18%), NRAS mutations in one patient (6%), but no HRAS, MET, PIK3CA, or BRAF mutations. Using strict and conservative criteria, 220 differentially expressed transcripts were found, with 36% up- and 64% downregulated. The transcripts were annotated using NCBI Entrez Gene, and computationally analyzed with the Ingenuity Pathway Analysis program. From these significantly changed expressions, the analysis identified 26 cancer-related transcripts and 16 transcripts related to mitochondrial dysfunction overlapping with three cancer-related genes. These 220 differentially expressed genes including microRNAs provide here a sufficiently large set to specifically define epithelial-myoepithelial carcinoma and to identify novel and potentially important targets for diagnosis, prognosis, and therapy of this cancer.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25546727      PMCID: PMC4845898          DOI: 10.1002/gcc.22238

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  32 in total

1.  miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.

Authors:  Li Jiao; Zhen Deng; Chuanliang Xu; Yongwei Yu; Yun Li; Chun Yang; Junyi Chen; Zhiyong Liu; Gang Huang; Long-Cheng Li; Yinghao Sun
Journal:  J Cell Physiol       Date:  2014-07       Impact factor: 6.384

2.  Principles of transcriptome analysis and gene expression quantification: an RNA-seq tutorial.

Authors:  Jochen B W Wolf
Journal:  Mol Ecol Resour       Date:  2013-04-27       Impact factor: 7.090

3.  Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

Authors:  Kolja Freier; Carsten Schwaenen; Carsten Sticht; Christa Flechtenmacher; Joachim Mühling; Christof Hofele; Bernhard Radlwimmer; Peter Lichter; Stefan Joos
Journal:  Oral Oncol       Date:  2006-06-27       Impact factor: 5.337

4.  MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma.

Authors:  C Yi; Q Wang; L Wang; Y Huang; L Li; L Liu; X Zhou; G Xie; T Kang; H Wang; M Zeng; J Ma; Y Zeng; J-P Yun
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

5.  miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer.

Authors:  S Uhlmann; J D Zhang; A Schwäger; H Mannsperger; Y Riazalhosseini; S Burmester; A Ward; U Korf; S Wiemann; O Sahin
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

6.  Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex.

Authors:  Jean-Marc Blouin; Graziella Penot; Martine Collinet; Magali Nacfer; Claude Forest; Pierre Laurent-Puig; Xavier Coumoul; Robert Barouki; Chantal Benelli; Sylvie Bortoli
Journal:  Int J Cancer       Date:  2010-10-08       Impact factor: 7.396

7.  Integrative approach for prioritizing cancer genes in sporadic colon cancer.

Authors:  James F Reid; Manuela Gariboldi; Viktorija Sokolova; Patrizia Capobianco; Andrea Lampis; Federica Perrone; Stefano Signoroni; Aurora Costa; Ermanno Leo; Silvana Pilotti; Marco A Pierotti
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

Review 8.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

9.  FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.

Authors:  Koichi Azuma; Akihiko Kawahara; Kahori Sonoda; Kazutaka Nakashima; Kousuke Tashiro; Kosuke Watari; Hiroto Izumi; Masayoshi Kage; Michihiko Kuwano; Mayumi Ono; Tomoaki Hoshino
Journal:  Oncotarget       Date:  2014-08-15

10.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

View more
  3 in total

Review 1.  Development of head and neck pathology in Europe.

Authors:  Henrik Hellquist; Abbas Agaimy; Göran Stenman; Alessandro Franchi; Alfons Nadal; Alena Skalova; Ilmo Leivo; Nina Zidar; Roderick H W Simpson; Pieter J Slootweg; Juan C Hernandez-Prera; Alfio Ferlito
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

Review 2.  Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.

Authors:  Rick Kamps; Rita D Brandão; Bianca J van den Bosch; Aimee D C Paulussen; Sofia Xanthoulea; Marinus J Blok; Andrea Romano
Journal:  Int J Mol Sci       Date:  2017-01-31       Impact factor: 5.923

3.  Decreased miRNA expression in Klinefelter syndrome.

Authors:  Laura Cimino; Michele Salemi; Rossella Cannarella; Rosita A Condorelli; Giorgio Giurato; Giovanna Marchese; Sandro La Vignera; Aldo E Calogero
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.